124 related articles for article (PubMed ID: 27174603)
1. Low-dose rate brachytherapy with I-125 seeds has an excellent 5-year outcome with few side effects in patients with low-risk prostate cancer.
Rasmusson E; Gunnlaugsson A; Kjellén E; Nilsson P; Einarsdottir M; Wieslander E; Fransson P; Ahlgen G; Blom R
Acta Oncol; 2016 Aug; 55(8):1016-21. PubMed ID: 27174603
[TBL] [Abstract][Full Text] [Related]
2. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
[TBL] [Abstract][Full Text] [Related]
3. Low-dose-rate brachytherapy for prostate cancer: outcomes at >10 years of follow-up.
Lazarev S; Thompson MR; Stone NN; Stock RG
BJU Int; 2018 May; 121(5):781-790. PubMed ID: 29319928
[TBL] [Abstract][Full Text] [Related]
4. Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions.
Fellin G; Mirri MA; Santoro L; Jereczek-Fossa BA; Divan C; Mussari S; Ziglio F; La Face B; Barbera F; Buglione M; Bandera L; Ghedi B; Di Muzio NG; Losa A; Mangili P; Nava L; Chiarlone R; Ciscognetti N; Gastaldi E; Cattani F; Spoto R; Vavassori A; Giglioli FR; Guarneri A; Cerboneschi V; Mignogna M; Paoluzzi M; Ravaglia V; Chiumento C; Clemente S; Fusco V; Santini R; Stefanacci M; Mangiacotti FP; Martini M; Palloni T; Schinaia G; Lazzari G; Silvano G; Magrini S; Ricardi U; Santoni R; Orecchia R
Br J Radiol; 2016 Sep; 89(1065):20150981. PubMed ID: 27384381
[TBL] [Abstract][Full Text] [Related]
5. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men agedGómez-Iturriaga Piña A; Crook J; Borg J; Lockwood G; Fleshner N
Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
[TBL] [Abstract][Full Text] [Related]
6. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
[TBL] [Abstract][Full Text] [Related]
7. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
8. Outcomes following iodine-125 prostate brachytherapy with or without neoadjuvant androgen deprivation.
Ohashi T; Yorozu A; Saito S; Momma T; Toya K; Nishiyama T; Yamashita S; Shiraishi Y; Shigematsu N
Radiother Oncol; 2013 Nov; 109(2):241-5. PubMed ID: 24183866
[TBL] [Abstract][Full Text] [Related]
9. A dose-response analysis of biochemical control outcomes after (125)I monotherapy for patients with favorable-risk prostate cancer.
Shiraishi Y; Yorozu A; Ohashi T; Toya K; Saito S; Nishiyama T; Yagi Y; Shigematsu N
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1069-75. PubMed ID: 25539368
[TBL] [Abstract][Full Text] [Related]
10. Impact of race on biochemical disease recurrence after prostate brachytherapy.
Yamoah K; Stone N; Stock R
Cancer; 2011 Dec; 117(24):5589-600. PubMed ID: 21692058
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer.
Burri RJ; Stone NN; Unger P; Stock RG
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1338-44. PubMed ID: 20138442
[TBL] [Abstract][Full Text] [Related]
12. Five-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK.
Dickinson PD; Malik J; Mandall P; Swindell R; Bottomley D; Hoskin P; Logue JP; Wylie JP
BJU Int; 2014 May; 113(5):748-53. PubMed ID: 24053230
[TBL] [Abstract][Full Text] [Related]
13. [Clinical outcome of intermediate risk prostate cancer treated with iodine 125 monotherapy: The Hotel-Dieu of Quebec experience].
Zebentout O; Apardian R; Beaulieu L; Harel F; Martin AG; Vigneault E
Cancer Radiother; 2010 Jun; 14(3):183-8. PubMed ID: 20418145
[TBL] [Abstract][Full Text] [Related]
14. Long-term oncological outcomes and toxicity in 597 men aged ≤60 years at time of low-dose-rate brachytherapy for localised prostate cancer.
Langley SEM; Soares R; Uribe J; Uribe-Lewis S; Money-Kyrle J; Perna C; Khaksar S; Laing R
BJU Int; 2018 Jan; 121(1):38-45. PubMed ID: 28670842
[TBL] [Abstract][Full Text] [Related]
15. Low-dose-rate prostate brachytherapy: 4-8 week postimplant prostate-specific antigen a novel predictor of biochemical failure-free survival.
Callaghan CM; Wang L; Alluri A; Lauve A; Boyer C; Russell W
Brachytherapy; 2017; 16(6):1119-1128. PubMed ID: 28844821
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic Ablative Radiotherapy Versus Low Dose Rate Brachytherapy or External Beam Radiotherapy: Propensity Score Matched Analyses of Canadian Data.
Loblaw A; Pickles T; Crook J; Martin AG; Vigneault E; Souhami L; Cury F; Morris J; Catton C; Lukka H; Cheung P; Sethukavalan P; Warner A; Yang Y; Rodrigues G;
Clin Oncol (R Coll Radiol); 2017 Mar; 29(3):161-170. PubMed ID: 27780694
[TBL] [Abstract][Full Text] [Related]
17. Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer.
Kollmeier MA; Fidaleo A; Pei X; Cohen G; Zaider M; Mo Q; Cox B; Yamada Y; Zelefsky MJ
BJU Int; 2013 Jun; 111(8):1231-6. PubMed ID: 23551568
[TBL] [Abstract][Full Text] [Related]
18. Low-dose-rate brachytherapy for patients with transurethral resection before implantation in prostate cancer. Longterm results.
Prada PJ; Anchuelo J; Blanco AG; Paya G; Cardenal J; Acuna E; Ferri M; Vazquez A; Pacheco M; Sanchez J
Int Braz J Urol; 2016; 42(1):47-52. PubMed ID: 27136466
[TBL] [Abstract][Full Text] [Related]
19. Segmental dosimetry, toxicity and long-term outcome in patients with prostate cancer treated with permanent seed implants.
Meyer A; Wassermann J; Warszawski-Baumann A; Baumann R; Machtens S; Karstens JH; Christiansen H; Merseburger A; Kuczyk MA; von Klot C
BJU Int; 2013 May; 111(6):897-904. PubMed ID: 23305079
[TBL] [Abstract][Full Text] [Related]
20. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.
Zelefsky MJ; Kuban DA; Levy LB; Potters L; Beyer DC; Blasko JC; Moran BJ; Ciezki JP; Zietman AL; Pisansky TM; Elshaikh M; Horwitz EM
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):327-33. PubMed ID: 17084558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
